Author

S. Stavrou

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 5 Organism:mouse· 4 Assay:DNA methylation· 2 Organism:human· 2 Approach:biophysical modeling· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

U. Timilsina· 4 shared S. Umthong· 3 shared A. Aguilera· 2 shared B. Lynch· 2 shared S. R. Ross· 2 shared A. Plianchaisuk· 1 shared A. Stablewski· 1 shared B. Waxman· 1 shared

Activity by Year

2018-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

U. Timilsina

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Determining the antiviral mechanism of MARCH2

S. Umthong, U. Timilsina, M. D'Angelo, S. Stavrou

This study identifies an amino acid critical for human MARCH2's antiviral function against HIV-1 and maps domains involved in restricting and binding HIV-1 envelope glycoproteins.

bioRxiv · Sep 18, 2023 · PreprintMicrobiology

SARS-CoV-2 ORF7a mutation found in BF.5 and BF.7 sublineages impacts its functions

U. Timilsina, S. Duffy, A. Plianchaisuk, J. Ito, K. Sato, S. Stavrou

The paper evaluates the effect of the H47Y mutation in ORF7a of SARS-CoV-2 BF.5 and BF.7 sublineages on its three main functions, finding it impairs IFN-I antagonism and MHC-I downregulation but not anti-SERINC5 function.

bioRxiv · Sep 6, 2023Microbiology

Elucidating the antiviral mechanism of different MARCH proteins

S. Umthong, B. Lynch, U. Timilsina, B. Waxman, E. B. Ivey, S. Stavrou

This study investigates the antiviral mechanisms of MARCH proteins by analyzing their effects on viral envelope glycoproteins in human and mouse models.

bioRxiv · Dec 22, 2020Microbiology

SERINC5 potently restricts retrovirus infection in vivo

U. Timilsina, S. Umthong, B. Lynch, A. Stablewski, S. Stavrou

This paper shows that SERINC5 restricts retrovirus infection in vivo, dependent on glyco-Gag and viral envelope, while SERINC3 has no antiviral role.

bioRxiv · May 19, 2020Microbiology

APOBEC3A Catalyzes Mutation and Drives Carcinogenesis In Vivo

E. Law, R. Levin-Klein, M. Jarvis, H. Kim, P. Argyris, M. Carpenter, G. Starrett, L. Larson, M. Burns, R. Vogel, S. Stavrou, A. Aguilera, S. Wagner, D. Largaespada, T. Starr, , R. Harris

This study shows APOBEC3A promotes tumorigenesis in mice and supports its role in causing mutations in human cancers.

bioRxiv · Dec 27, 2019Cancer Biology

DDX41 recognizes RNA/DNA retroviral reverse transcripts and is critical for in vivo control of MLV infection

S. Stavrou, A. Aguilera, K. Blouch, S. R. Ross

This study identifies DDX41 as a sensor for retroviral RNA/DNA hybrids and shows its critical role in controlling MLV infection in vivo, alongside cGAS.

bioRxiv · May 2, 2018Microbiology